Stepped Collaborative Care Targeting Posttraumatic Stress Disorder Symptoms and Comorbidity for US Trauma Care Systems: A Randomized Clinical Trial.


Journal

JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553

Informations de publication

Date de publication:
01 05 2021
Historique:
pubmed: 11 3 2021
medline: 27 1 2022
entrez: 10 3 2021
Statut: ppublish

Résumé

To date, few multisite investigations have evaluated early interventions for injured patients with posttraumatic stress disorder (PTSD) symptoms. To simultaneously assess the effectiveness and implementation of a brief stepped collaborative care intervention targeting PTSD and comorbidity. A stepped-wedge cluster randomized clinical trial was conducted at 25 US level I trauma centers. Participants included hospitalized survivors of physical injury who underwent a 2-step evaluation for PTSD symptoms. Patients reporting high levels of distress on the PTSD Checklist (PCL-C) were randomized (N = 635) per the stepped-wedge protocol to enhanced usual care control (n = 370) or intervention (n = 265) conditions. The study was conducted from January 4, 2016, through November 2018. Data analysis was performed from November 4, 2019, to December 8, 2020. The Trauma Survivors Outcomes and Support collaborative care intervention included proactive injury case management that assisted patients transitioning from hospital inpatient to outpatient and community settings. The intervention also integrated evidence-based pharmacotherapy and psychotherapeutic elements targeting PTSD symptoms and comorbidity. The primary study outcome was PTSD symptoms assessed with the PCL-C at baseline in the surgical ward and at 3, 6, and 12 months postinjury. Secondary outcomes included depressive symptoms, alcohol use, and physical function. Subgroup analyses examined the effect of baseline risk factors for enduring PTSD and quality of protocol implementation on study outcomes. Primary statistical analyses were conducted using the intent-to-treat sample. A total of 327 men (51.5%) were included in analysis; mean (SD) age was 39.0 (14.2) years. The investigation attained follow-up of 75% to 80% of the participants at 3 to 12 months. The intervention lasted a mean (SD) of 122 (132) minutes. Mixed model regression analyses revealed statistically significant changes in PCL-C scores for intervention patients compared with control patients at 6 months (difference, -2.57; 95% CI, -5.12 to -0.03; effect size, 0.18; P < .05) but not 12 months (difference, -1.27; 95% CI, -4.26 to 1.73; effect size, 0.08; P = .35). Subgroup analyses revealed larger PTSD treatment effects for patients with 3 or more baseline risk factors for enduring PTSD and for patients, including firearm injury survivors, treated at trauma centers with good or excellent protocol implementation. Intervention effects for secondary outcomes did not attain statistical significance. A brief stepped collaborative care intervention was associated with significant 6-month but not 12-month PTSD symptom reductions. Greater baseline PTSD risk and good or excellent trauma center protocol implementation were associated with larger PTSD treatment effects. Orchestrated efforts targeting policy and funding should systematically incorporate the study findings into national trauma center requirements and verification criteria. ClinicalTrials.gov Identifier: NCT02655354.

Identifiants

pubmed: 33688908
pii: 2776953
doi: 10.1001/jamasurg.2021.0131
pmc: PMC7948109
doi:

Banques de données

ClinicalTrials.gov
['NCT02655354']

Types de publication

Comparative Study Journal Article Multicenter Study Pragmatic Clinical Trial Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

430-474

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Auteurs

Douglas Zatzick (D)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Harborview Injury Prevention and Research Center, University of Washington School of Medicine, Seattle.

Gregory Jurkovich (G)

Department of Surgery, UC Davis School of Medicine, Sacramento, California.

Patrick Heagerty (P)

Department of Biostatistics, University of Washington School of Public Health, Seattle.

Joan Russo (J)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

Doyanne Darnell (D)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

Lea Parker (L)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Department of Psychology, Drexel University College of Arts and Sciences, Philadelphia, Pennsylvania.

Michelle K Roberts (MK)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle.

Rddhi Moodliar (R)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.
Department of Psychology, University of California, Los Angeles.

Allison Engstrom (A)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

Jin Wang (J)

Harborview Injury Prevention and Research Center, University of Washington School of Medicine, Seattle.

Eileen Bulger (E)

Department of Surgery, University of Washington School of Medicine, Seattle.

Lauren Whiteside (L)

Department of Emergency Medicine, University of Washington School of Medicine, Seattle.

Deepika Nehra (D)

Department of Surgery, University of Washington School of Medicine, Seattle.

Lawrence A Palinkas (LA)

Department of Children, Youth and Families, USC Suzanne Dworak-Peck School of Social Work, Los Angeles, California.

Kathleen Moloney (K)

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

Ronald Maier (R)

Department of Surgery, University of Washington School of Medicine, Seattle.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH